Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-21. (Cancelled)

22. (New) A method for producing denatured lipoprotein, comprising:
freezing a solution containing lipoprotein to produce a frozen solution; and
melting the frozen solution to produce a solution containing denatured lipoprotein.

23. (New) The method according to claim 22, wherein said denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

24. (New) The method according to claim 22, wherein the lipoprotein is at least one selected from the group consisting of chyromicron, VLDL, LDL, Lp(a), HDL2 and HDL3.

25. (New) A denatured lipoprotein produced by the method according to claim 22.

26. (New) The denatured lipoprotein according to claim 25, wherein said denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

27. (New) A method for producing stabilized denatured lipoprotein, comprising:
freezing a solution containing lipoprotein to produce a frozen solution;
melting the frozen solution to produce a solution containing denatured lipoprotein; and
freeze-drying the solution.

28. (New) The method according to claim 27, wherein said denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

29. (New) The method according to claim 27, wherein the lipoprotein is at least one selected from the group consisting of chyromicron, VLDL, LDL, Lp(a), HDL2 and HDL3.

30. (New) A stabilized denatured lipoprotein produced by the method according to claim 27.

31. (New) The stabilized denatured lipoprotein according to claim 30, wherein said stabilized denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

32. (New) A method for producing stabilized denatured lipoprotein, comprising:
freezing a solution containing lipoprotein to produce a frozen solution;
melting the frozen solution to produce a solution containing denatured lipoprotein;
adding a stabilizer to the solution; and
freeze-drying the solution.

33. (New) The method according to claim 32, wherein said denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

34. (New) The method according to claim 32, wherein the lipoprotein is at least one selected from the group consisting of chyromicron, VLDL, LDL, Lp(a), HDL2 and HDL3.

35. (New) A stabilized denatured lipoprotein produced by the method according to claim 32.

36. (New) The stabilized denatured lipoprotein according to claim 35, wherein said denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

37. (New) A method for determining denatured lipoprotein in a sample, comprising:

selecting the denatured lipoprotein according to claim 25;

reacting the sample with an antibody which binds to the denatured lipoprotein;

measuring the reactivity of the antibody with the sample; and

comparing the reactivity with a calibration curve previously formed from the denatured lipoprotein.

38. (New) The method according to claim 37, wherein said determination is immunological determination.

39. (New) The method according to claim 38, wherein said immunological determination is selected from among radio immunoassay, enzyme immunoassay, fluoroimmunoassay, luminescent immunoassay, agglutination immunoassay, immunonephelometry, and nephelometric immunoassay.

40. (New) The method according to claim 39, wherein said method for immunological determination is a competitive method or a sandwich method.

41. (New) The method according to claim 37, wherein said denatured lipoprotein is a standard substance for determining denatured lipoprotein in blood or an experimental reagent for investigating the physiological role or the physiological activity of denatured lipoprotein.

42. (New) A method for determining denatured lipoprotein in a sample, comprising:

selecting the stabilized denatured lipoprotein according to claim 30;

reacting the sample with an antibody which binds to the denatured lipoprotein;

measuring the reactivity of the antibody with the sample; and

comparing the reactivity with a calibration curve previously formed from the denatured lipoprotein.

43. (New) The method according to claim 42, wherein said determination is immunological determination.

44. (New) The method according to claim 43, wherein said immunological determination is selected from among radio immunoassay, enzyme immunoassay, fluoroimmunoassay, luminescent immunoassay, agglutination immunoassay, immunonephelometry, and nephelometric immunoassay.

45. (New) The method according to claim 44, wherein said method for immunological determination is a competitive method or a sandwich method.

46. (New) The method according to claim 42, wherein said denatured lipoprotein is a standard substance for determining denatured lipoprotein in blood or an experimental reagent for investigating the physiological role or the physiological activity of denatured lipoprotein.

47. (New) A method for determining denatured lipoprotein in a sample, comprising:

selecting the stabilized denatured lipoprotein according to claim 35;

reacting the sample with an antibody which binds to the denatured lipoprotein;

measuring the reactivity of the antibody with the sample; and

comparing the reactivity with a calibration curve previously formed from the denatured lipoprotein.

48. (New) The method according to claim 47, wherein said determination is immunological determination.

49. (New) The method according to claim 48, wherein said immunological determination is selected from among radio immunoassay, enzyme immunoassay, fluoroimmunoassay, luminescent immunoassay, agglutination immunoassay, immunonephelometry, and nephelometric immunoassay.

50. (New) The method according to claim 49, wherein said method for immunological determination is a competitive method or a sandwich method.

51. (New) The method according to claim 47, wherein said denatured lipoprotein is a standard substance for determining denatured lipoprotein in blood or an experimental reagent for investigating the physiological role or the physiological activity of denatured lipoprotein.

52. (New) A reagent kit for determining denatured lipoprotein, comprising the denatured lipoprotein according to claim 25 as a standard substance.

53. (New) A reagent kit for determining denatured lipoprotein, comprising the stabilized denatured lipoprotein according to claim 30 as a standard substance.

54. (New) A reagent kit for determining denatured lipoprotein, comprising the stabilized denatured lipoprotein according to claim 35 as a standard substance.

55. (New) A reagent kit for determining denatured lipoprotein, comprising a diluting liquid for a sample, a solid phase formed by immobilizing an antibody, a reaction buffer, a washing solution, a labeled secondary antibody, a detecting reagent, and the whole or part of the denatured lipoprotein set forth in claim 25 as a standard substance as component elements.

56. (New) A reagent kit for determining denatured lipoprotein, comprising a diluting liquid for a sample, a solid phase formed by immobilizing an antibody, a reaction buffer, a washing solution, a labeled secondary antibody, a detecting reagent, and the whole or part of the stabilized denatured lipoprotein set forth in claim 30 as a standard substance as component elements.

57. (New) A reagent kit for determining denatured lipoprotein, comprising a diluting liquid for a sample, a solid phase formed by immobilizing an antibody, a reaction buffer, a washing solution, a labeled secondary antibody, a detecting reagent, and the whole or part of the stabilized denatured lipoprotein set forth in claim 35 as a standard substance as component elements.